Please enable Javascript
Timothy A. Richardson, MD
Timothy A. Richardson, MD
Timothy A. Richardson, MD, Wichita Urology
Articles by Timothy A. Richardson, MD
The Ideal Patients for TAR-200 and Barriers to Treatment Access
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
In the final segment of the roundtable, the panel debates the real-world integration of new therapies into everyday practice.
View More
Patient ID, Protocol and Procedure in NMIBC
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
In part five of this NMIBC roundtable, the panelists discuss integrating new therapies such as TAR-200 into clinical practice
View More
SunRISe-1 Data: Benefits of the Pretzel Device and Gemcitabine Monotherapy
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
Part four of this roundtable series examines the SunRISe-1 trial results for high-risk NMIBC.
View More
Where We Were and Where We Are in NMIBC Trials and Therapies
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
The panelists discuss advancements in NMIBC treatment in part three of this roundtable, including pembrolizumab and TAR-200.
View More
Treating BCG-Refractory Disease and Explaining NMIBC Treatment Options to Patients
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
Part two of this roundtable explores intravesical and systemic therapies, and the importance of accurate risk stratification.
View More
Novel Therapeutics and Personalized Therapies in NMIBC
Gordon Brown, DO
Non-Muscle Invasive Urothelial Carcinoma
|
December 5, 2024
The first part of this roundtable focuses on recent trial data, the role of TUR quality, and precision medicine for NMIBC.
View More